University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Boris C. Bastian, MD, PhD

Boris C. Bastian, MD, PhD

Professor of Dermatology and Pathology, University of California, San Francisco
Gerson and Barbara Bass Bakar Distinguished Professor in Cancer Research, UCSF

Cancer Center Program Memberships

Cancer Genetics

Research Summary

I am a dermatologist and dermatopathologist with expertise in diagnosing and treating patients with cutaneous neoplasms. I have expertise in molecular cancer genetics and molecular pathology. I direct the Clinical Cancer Genomics Laboratory at UCSF, which performs genomic analyses of tumor samples of patients seen at the UCSF Helen Diller Family Comprehensive Cancer Center and have additional clinical responsibilities in the in the Dermatopathology Section of the Departments of Dermatology and Pathology. I am an investigator at the Helen Diller Family Comprehensive Cancer Center at UCSF. My research focuses on the molecular genetics of cutaneous neoplasms, with a particular emphasis on the discovery of genetic alterations useful for diagnosis, classification, and therapy of melanocytic neoplasms.

Education

Humboldt-Gymnasium, Solingen, Germany, Baccalaureate, 1980
University of Munich, Germany, M.D., 1988, Medicine
University of Munich, Germany, Dr. med., 1989, Laboratory Medicine
University of Wurzburg, Germany, Residency, 1994, Dermatology
University of California, San Francisco, Postdoctoral, 1999, Cancer Genetics


Professional Experience

  • 1986-1989
    Dissertation 'Development and Characterization of an enzymatic assay for human pancreatic phospholipase A2'
  • 1988-89
    Fellowship, Dept. of Hematology, Ludwig-Maximilian-University, Munich, Germany
  • 1989-1994
    Residency, Dermatology, Dept. of Dermatology, University of Würzburg, Germany
  • 1993
    German board certification for Dermatology
  • 1995
    German board certification Allergy and Immunology
  • 1994-1997
    Attending Physician, Dept. of Dermatology, University of Würzburg, Germany
  • 1995-1997
    Director of the Dermatopathology Section, Dept. of Dermatology, University of Würzburg, Germany
  • 1997-1999
    Postdoctoral Fellowship, Cancer Genetics Group, Cancer Center at UCSF
  • 1999-2002
    Assistant Clinical Professor, Dept. of Dermatology and Pathology, UCSF
  • 2002-2004
    Assistant Professor in Residence, Department of Dermatology and Assistant Clinical Professor, Department of Pathology, UCSF
  • 7/2004-2008
    Associate Professor in Residence, Department of Dermatology and Associate Clinical Professor, Department of Pathology, UCSF
  • 7/2008
    Professor in Residence, Department of Dermatology and Clinical Professor, Department of Pathology, UCSF
  • 9/2008
    Leader, Cutaneous Oncology Program, UCSF
  • 4/2010-8/11
    Chairman, Department of Pathology, and Member, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center
  • 9/2011-present
    Professor of Dermatology and Pathology, University of California, San Francisco

Honors & Awards

  • 1995
    Graduate Stipend of the Novartis Foundation for Therapeutic Research
  • 1997
    Habilitandenstipendium of the German Research Society (Deutsche Forschungsgemeinschaft)
  • 2000
    American Melanoma Foundation Research Award
  • 2001
    American Skin Association Research Scientist Development Award
  • 2005
    Hermann Pinkus Lectureship and Award, American Society of Dermatopathology
  • 2006
    Stewart Trust Award
  • 2007
    Melanoma Research Foundation Individual Investigator Award
  • 2008
    Abby S. and Howard P. Milstein Innovation Award for Skin Cancer Research, American Skin Association
  • 2011-2013
    President, Society of Melanoma Research
  • 2011
    German National Academy of Science (Leopoldina)

Selected Publications

  1. Chiba K, Lorbeer FK, Shain AH, McSwiggen DT, Schruf E, Oh A, Ryu J, Darzacq X, Bastian BC, Hockemeyer D. Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism. Science. 2017 Aug 17.
    View on PubMed
  2. Shain AH, Bastian BC. Filling the gaps in the genomic catalogue of melanoma subtypes. Pigment Cell Melanoma Res. 2017 Jun 28.
    View on PubMed
  3. Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017 Jun 01; 28(6):1380-1387.
    View on PubMed
  4. Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, Coupland SE, Roose JP, Bastian BC. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell. 2017 May 08; 31(5):685-696.e6.
    View on PubMed
  5. Eluri M, Feneran A, Bordeaux JS, Ruben B, Ostrowski S, Bastian BC, Honda K. Multiple Merkel cell carcinomas: Late metastasis or multiple primary tumors? A molecular study. JAAD Case Rep. 2017 Mar; 3(2):131-134.
    View on PubMed
  6. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 Mar 13; 7:44206.
    View on PubMed
  7. Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, Bastian BC, Rabban JT, Garg K, Zaloudek C, Solomon DA. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod Pathol. 2016 Nov 04.
    View on PubMed
  8. Yeh I, Tee MK, Botton T, Shain AH, Sparatta AJ, Gagnon A, Vemula SS, Garrido MC, Nakamaru K, Isoyama T, McCalmont TH, LeBoit PE, Bastian BC. NTRK3 kinase fusions in Spitz tumours. J Pathol. 2016 Nov; 240(3):282-290.
    View on PubMed
  9. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Jin LW, Bastian BC, Bollen AW, Perry A, Nicolaides T, Solomon DA, Shieh JT. Activating NRF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. Acta Neuropathol. 2016 Sep 13.
    View on PubMed
  10. Liu SY, Joseph NM, Ravindranathan A, Stohr BA, Greenland NY, Vohra P, Hosfield E, Yeh I, Talevich E, Onodera C, Van Ziffle JA, Grenert JP, Bastian BC, Chen YY, Krings G. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol. 2016 Jun 3.
    View on PubMed
  11. Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016 Jun; 16(6):345-58.
    View on PubMed
  12. Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol. 2016 Apr; 12(4):e1004873.
    View on PubMed
  13. Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016 Jul; 29(4):404-16.
    View on PubMed
  14. Shain AH, Bastian BC. The Genetic Evolution of Melanoma. N Engl J Med. 2016 Mar 10; 374(10):993-6.
    View on PubMed
  15. Kline CN, Joseph NM, Grenert JP, van Ziffle J, Yeh I, Bastian BC, Mueller S, Solomon DA. Inactivating MUTYH germline mutations in pediatric patients with high-grade midline gliomas. Neuro Oncol. 2016 May; 18(5):752-3.
    View on PubMed
  16. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D'Arrigo C, Robson A, Bastian BC. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015 Nov 12; 373(20):1926-36.
    View on PubMed
  17. Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, Chung J, Wang NJ, Kakavand H, Mann GJ, Thompson JF, Wiesner T, Roy R, Olshen AB, Gagnon A, Gray JW, Huh N, Hur JS, Busam KJ, Scolyer RA, Cho RJ, Murali R, Bastian BC. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015 Oct; 47(10):1194-9.
    View on PubMed
  18. Conde-Perez A, Gros G, Longvert C, Pedersen M, Petit V, Aktary Z, Viros A, Gesbert F, Delmas V, Rambow F, Bastian BC, Campbell AD, Colombo S, Puig I, Bellacosa A, Sansom O, Marais R, Van Kempen LC, Larue L. A caveolin-dependent and PI3K/AKT-independent role of PTEN in ß-catenin transcriptional activity. Nat Commun. 2015; 6:8093.
    View on PubMed
  19. Sanborn JZ, Chung J, Purdom E, Wang NJ, Kakavand H, Wilmott JS, Butler T, Thompson JF, Mann GJ, Haydu LE, Saw RP, Busam KJ, Lo RS, Collisson EA, Hur JS, Spellman PT, Cleaver JE, Gray JW, Huh N, Murali R, Scolyer RA, Bastian BC, Cho RJ. Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A. 2015 Sep 1; 112(35):10995-1000.
    View on PubMed
  20. Singh AD, Schoenfield LA, Bastian BC, Aziz HA, Marino MJ, Biscotti CV. Congenital uveal melanoma? Surv Ophthalmol. 2016 Jan-Feb; 61(1):59-64.
    View on PubMed

Go to UCSF Profiles, powered by CTSI